Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650? excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650? is a trademark of Sirigen Group Ltd.

ELISA Capture^3,4 and ELISPOT Capture⁵: The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard.
Flow Cytometry^{2-4,7,8,11,12}: The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations.
Neutralization^6,9: The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IL-17 bioactivity in vivo and in vitro (Cat. No. 506906).

1. Kennedy J, et al. 1996. J. Interferon Cytokine Res. 16:611.
2. Schubert D, et al. 2004. J. Immunol. 172:4503. (ICFC)
3. Infante-Duarte C, et al. 2000. J. Immunol. 165:6107. (ICFC, ELISA Capture)
4. Harrington LE, et al. 2005. Nature Immunol. doi:10.1038/ni1254. (ICFC, ELISA Capture)
5. Nekrasova T, et al. 2005. J. Immunol. 175:2734. (ELISPOT Capture)
6. Yen D, et al. 2006. J. Clin. Invest. 116:1310. (Neut)
7. Ehirchiou D, et al. 2007. J. Exp. Med. 204:1519. (ICFC)
8. Kang SG, et al. 2007. J. Immunol. 179:3724. (ICFC)
9. Smith E, et al. 2008. J. Immunol. 181:1357. (Neut) PubMed
10. Neufert C, et al. 2007. Eur. J. Immunol. 37:1809. PubMed
11. Wang C, et al. 2009. Mucosal Immunol 2:173. (ICFC) PubMed
12. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (ICFC) PubMed
13. Kivis?kk P, et al. 2009. Ann. Neurol. 65:457. PubMed
14. Cooney LA, et al. 2011. J. Immunol. 187:4440. PubMed
15. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
16. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed

1. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
2. Marques RM, et al. 2021. Cell Death Differ. 28:3140. PubMed
3. Nakatsuji T, et al. 2021. Nat Med. 27:700. PubMed
4. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
5. Li A, et al. 2020. J Virol. 94:00:00. PubMed
6. Li H, et al. 2021. Protein Cell. Online ahead of print. PubMed
7. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
8. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Numasaki M, et al. 2002. Blood 101:2620.
3. Fossiez F, et al. 1996. J. Exp. Med. 183:2593.
4. Yao Z, et al. 1997. Cytokine 9:794.
5. Dong C. 2006. Nat. Rev. Immunol. 6:329.
6. Hofstetter HH, et al. 2005 Cell. Immunol. 237:123.